Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study
Maria Vittoria Dieci(Istituto Oncologico Veneto), Gian Luca De Salvo(Istituto Oncologico Veneto), Laura Merlini(Azienda Ospedale - Università Padova), Fable Zustovich, Emilio Bria(Università Cattolica del Sacro Cuore), Valentina Guarneri(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Paolo Morandi(Ospedale dell' Angelo), Cristina Oliani(Ospedale Maggiore), Silvia Michieletto(Istituto Oncologico Veneto), Tommaso Giarratano(Istituto Oncologico Veneto), Enrico Orvieto(AULSS 2 Marca Trevigiana), Pierluigi Bullian, Marta Mion(University of Padua), Paola Del Bianco(Istituto Oncologico Veneto), Gaia Griguolo(University of North Carolina at Chapel Hill), Stefania Gori(Ospedale Sacro Cuore Don Calabria), Tania Saibene(Istituti di Ricovero e Cura a Carattere Scientifico)
Cited by 37
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|1k
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830